Last reviewed · How we verify
MK-0431/ONO-5435
MK-0431/ONO-5435 is a DPP-4 inhibitor Small molecule drug developed by Ono Pharmaceutical Co. Ltd. It is currently in Phase 3 development for Type 2 diabetes mellitus.
MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | MK-0431/ONO-5435 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug inhibits DPP-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing degradation of these incretin hormones, the drug enhances their glucose-dependent stimulation of insulin secretion and suppression of glucagon, thereby lowering blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) (PHASE2)
- Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136) (PHASE3)
- MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104) (PHASE3)
- MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes (PHASE3)
- MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus (PHASE3)
- Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-0431/ONO-5435 CI brief — competitive landscape report
- MK-0431/ONO-5435 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI
Frequently asked questions about MK-0431/ONO-5435
What is MK-0431/ONO-5435?
How does MK-0431/ONO-5435 work?
What is MK-0431/ONO-5435 used for?
Who makes MK-0431/ONO-5435?
What drug class is MK-0431/ONO-5435 in?
What development phase is MK-0431/ONO-5435 in?
What are the side effects of MK-0431/ONO-5435?
What does MK-0431/ONO-5435 target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4 (Dipeptidyl peptidase-4)
- Manufacturer: Ono Pharmaceutical Co. Ltd — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: MK-0431/ONO-5435 vs similar drugs
- Pricing: MK-0431/ONO-5435 cost, discount & access